Instructional Biology Files Patent for Personalized Therapeutics Platform

Instructional Biology, a biotechnology company based in San Diego, California, has filed a patent for a platform designed to deliver therapeutics made by the body for the body. This 15-year effort by sole inventor Boris Markosian integrates advanced science, artificial intelligence, bio-manufacturing, laser pathogen reduction, exosome delivery, and digital twin-guided therapeutics.

The pharmaceutical industry, which has traditionally focused on synthetic chemical drugs designed to push hard on a single molecular target, is under strain. According to the CDC, nearly 80,000 people died in the U.S. alone from opioid-related overdose in 2023. This model, which built the modern pharmaceutical industry, is now facing significant challenges. About $300 billion in branded drug revenue is expected to lose patent protection by 2030. Biology rarely works one target at a time, and Instructional Biology is built to work with that coordination rather than override it.

The company's platform aims to capture natural biologics the body already makes to heal and repair. It uses the body's own language to deliver personalized medicine.

First, it addresses keeping delicate molecules alive. The body's natural healing signals are made of fragile proteins, which lose their shape and function when exposed to heat. The filing describes a protocol that manufactures these materials at temperatures held safely below the point where the most delicate protein begins to unravel. Natural signals are driven by the specific form of the molecules, so the bio-manufacturing process monitors their conformation continuously to keep them in their native state.

Second, the application describes making medicine safe without ruining it. Conventional safety steps can damage the very proteins they are meant to protect. The application outlines precisely tuned lasers designed to reduce pathogens while staying below the energy needed to break peptide bonds, the chemical links that hold proteins together.

Third, the platform maps the body's conversations through the Advanced Science AI Platform, or ASAP. Cells communicate constantly through signaling molecules, and ASAP maps those conversations as a web of connections. This map then suggests which signals might matter for a given condition. Markosian describes it as escaping the "flatland" of traditional AI by modeling biology in a shape that better fits the hierarchical nature of biological processes.

The application discloses a broad range of potential uses, including postpartum depression, pain, opioid-related conditions, wound healing, and skin aging. Furthermore, it describes ways to tailor treatments to individual patients through the ASAP platform, using digital twins. These are possibilities, not promises. The technology is at the research and development stage, and no product has been approved by any regulatory agency. Instructional Biology is seeking research partners, including an independent laboratory to begin validating the platform, and welcomes inquiries from prospective partners and investors.